NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
Jul. 31, 2018
EMERYVILLE, Calif.--(BUSINESS WIRE)--Jul 31, 2018--NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.
The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time August 13, 2018, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 1078758. The call will also be archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005349/en/
CONTACT: NovaBay Pharmaceuticals, Inc.
Jack McGovern, 510-899-8800
Chief Financial Officer
LHA Investor Relations
Jody Cain, 310-691-7100
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS GENERAL HEALTH
SOURCE: NovaBay Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 07/31/2018 06:50 AM/DISC: 07/31/2018 06:51 AM